Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists

医学 耐受性 荟萃分析 胰高血糖素样肽1受体 药理学 内科学 受体 重症监护医学 兴奋剂 不利影响
作者
Mattía Galli,Stefano Benenati,Claudio Laudani,Beatrice Simeone,Gianmarco Sarto,Luis Ortega‐Paz,Erica Rocco,Marco Bernardi,Luigi Spadafora,Domenico D’Amario,Ernesto Greco,Giacomo Frati,Massimo Federici,Roxana Mehran,Filippo Crea,Dominick Joseph Angiolillo,Sebastiano Sciarretta
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:86 (20): 1805-1819 被引量:139
标识
DOI:10.1016/j.jacc.2025.08.027
摘要

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined. OBJECTIVES: Previous meta-analyses of GLP-1 RAs have been limited by restricted populations, omission of recent trials, or incomplete safety synthesis; this study integrates the latest evidence across 21 randomized controlled trials and diverse populations using advanced meta-analytic methods. METHODS: Randomized controlled trials comparing GLP-1 RAs vs controls or placebo were included. Analyses were conducted in prespecified subgroups based on the GLP-1 RA used. Prespecified subgroups according to diabetes mellitus, kidney function, obesity, or heart failure were also performed. Main outcomes comprised mortality (all-cause and CV), trial-defined major adverse cardiovascular events (MACE) and serious adverse events. GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analyses were performed to evaluate certainty and conclusiveness of findings, respectively. RESULTS: A total of 21 trials encompassing 99,599 patients were included. Eight different GLP-1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, and tirzepatide), each administered at therapeutic doses and compared vs placebo or controls. Mean follow-up duration was 2.4 years. We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls. GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders. There were no differences in stroke, pancreatitis, or neoplasm between groups. Results were mostly consistent across subgroups. Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles. CONCLUSIONS: GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased gastrointestinal and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis]; CRD420251032222).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
大个的应助被drizzle采纳,获得10
1秒前
1秒前
1秒前
1秒前
123发布了新的文献求助10
2秒前
在水一方的应助被纪十三采纳,获得30
2秒前
地雷完成签到 ,获得积分10
2秒前
cjk关注了科研通微信公众号
3秒前
3秒前
4秒前
4秒前
山海不远发布了新的文献求助10
4秒前
4秒前
跳跃靖发布了新的文献求助10
5秒前
5秒前
羽6发布了新的文献求助10
5秒前
西西发布了新的文献求助10
5秒前
小淡发布了新的文献求助10
6秒前
6秒前
6秒前
Yuan88发布了新的文献求助30
6秒前
7秒前
lay完成签到,获得积分10
7秒前
7秒前
7秒前
cuury5210完成签到,获得积分10
7秒前
zzt完成签到,获得积分10
8秒前
英姑的应助被开心的中心采纳,获得10
8秒前
8秒前
8秒前
ditto发布了新的文献求助10
9秒前
lay发布了新的文献求助10
9秒前
木木发布了新的文献求助10
9秒前
Yuan88发布了新的文献求助10
9秒前
10秒前
yjt发布了新的文献求助10
10秒前
10秒前
汉堡包的应助被公爵采纳,获得30
10秒前
在水一方的应助被ea采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184220
求助须知:如何正确求助?哪些是违规求助? 9573266
关于积分的说明 21830447
捐赠科研通 7781246
什么是DOI,文献DOI怎么找? 3434248
关于科研通互助平台的介绍 2558373
邀请新用户注册赠送积分活动 2480784